Delos Cosgrove Buys Shares of Hims & Hers Health

Delos Cosgrove purchased 3,656 shares of Hims & Hers Health, Inc. on June 11, 2026.

Written by EarningsIQ · Published Jun 15, 2026, 6:03 PM EDT

Key Points

Delos Cosgrove bought 3,656 shares of Hims & Hers Health, Inc. on June 11, 2026, with the stock trading at $26.82.
Hims & Hers Health has a market cap of approximately $6.21 billion and a forward P/E ratio of 30.13.
Insider trading at Hims & Hers Health included both buying and selling activities by various executives in June 2026.

On June 11, 2026, Delos Cosgrove purchased 3,656 shares of Hims & Hers Health, Inc. (NYSE:HIMS). This insider transaction was not part of a pre-planned trading program. The shares were acquired when the stock was trading at $26.82.

Hims & Hers Health Stock Snapshot

Shares of NYSE:HIMS traded near $26.82. Hims & Hers Health boasts a market cap of about $6.21 billion and a forward P/E ratio of 30.13. The stock has experienced significant volatility, with a 52-week low of $13.74 and a high of $70.43. Its 50-day moving average is $25.63, while the 200-day moving average is $33.57. The company has a current ratio of 1.69 and a quick ratio of 1.45, but a high debt-to-equity ratio of 253.73.

Recent Earnings

Hims & Hers Health reported revenue of approximately $2.37 billion, reflecting a modest growth rate of 3.8%. However, the company is not yet profitable, with a net margin of -0.56% and a return on equity of -2.66%. The next earnings report is scheduled for August 10, 2026.

Insider Buying and Selling at Hims & Hers Health, Inc.

In addition to Delos Cosgrove's purchase, several other insiders were active in June 2026. Christopher Payne bought 10,687 shares, while David Wells acquired 957 shares. On the selling side, Payne also sold 10,687 shares, and Anja Manuel sold 10,040 shares. Patrick Harrison Carroll, the Chief Medical Officer, sold 435 shares.

Analysts Set New Price Targets

Analysts have maintained a cautious view on Hims & Hers Health. On May 26, 2026, B of A Securities maintained a 'hold' rating with a $25 price target. Similarly, Truist Securities kept a 'hold' rating with a $23 target on May 22. Meanwhile, JP Morgan and Needham maintained 'buy' ratings, with targets of $33 and $35, respectively, on May 12.

About Hims & Hers Health

Hims & Hers Health, Inc. is a healthcare company based in San Francisco, California. It operates a health and wellness platform that connects consumers with licensed healthcare professionals. The company provides a range of prescription and non-prescription health products, focusing on areas like skincare, sexual health, and hair care. Founded by Andrew Dudum, it serves customers across the United States, Europe, and other international markets.

Bottom Line

Delos Cosgrove's recent purchase of Hims & Hers Health shares highlights ongoing insider interest in the company. With a market cap of over $6 billion, the company remains a significant player in the healthcare sector. Investors will be watching closely for the next earnings report in August, which could provide further insights into its financial performance. Remember, insider transactions like these are reported after the fact and don't necessarily predict future stock performance.